alzhub.org
Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

Newest studies

Every summary in our library, newest first, as a dated timeline.

What "newest" means here

The most recent study in this library is dated 2026-11-01 (Paths of Aging Minds: Health Journeys of Older Adults with Mild Cognitive Impairment). This is our summary library, not a news wire — it is added to in batches, so the newest entry may not be the newest paper published anywhere.

Entries are sorted strictly by publication date, newest first. 26489 of the 27380 entries carry a full day-level date. 65 have no date recorded at all and are placed by publication year, at the start of that year; those are marked "no date recorded" below so you can see where the ordering is a best effort rather than a fact.

Prefer a reader? Subscribe to the Atom feed. Want them sorted by subject or by score instead? Browse the research library.

Showing 25,076–25,100 of 27,380 studies, newest first · page 1004 of 1096.

October 2001 3

  1. 2001-10-01

    A comprehensive, stage-sensitive model of grief in dementia caregiving

    ✓ Peer-reviewed Caregiving The Gerontologist

    Key finding: Significant differences emerged between spouse and adult-child caregiver groups as a whole and as a function of Clinical Dementia Rating impairment level. +1 more finding

    Full summary, score breakdown and related studies → Original source

  2. 2001-10-01

    Interventions to reduce the burden of caregiving for an adult with dementia: a meta-analysis

    ✓ Peer-reviewed Caregiving Research in nursing & health

    Key finding: Because of conflicting results, in order to clarify the state of the science it was necessary to do a systematic analysis of the literature on research testing the effect of interventions on the burden of persons caring for family members with dementia. +2 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2001-10-01

    The Alzheimer's Disease Assessment Scale: evaluation of psychometric properties and patterns of cognitive decline in multicenter clinical trials of mild to moderate Alzheimer's disease

    ✓ Peer-reviewed Treatments Alzheimer disease and associated disorders

    Key finding: In 6-month trials, measurement error makes a substantial contribution to the variance in ADAS-Cog change scores.

    Full summary, score breakdown and related studies → Original source

September 2001 22

  1. 2001-09-25

    beta-amyloid peptides enhance alpha-synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease

    ✓ Peer-reviewed Lewy body dementia Proceedings of the National Academy of Sciences of the United States of America

    Key finding: Alzheimer's disease and Parkinson's disease are associated with the cerebral accumulation of beta-amyloid and alpha-synuclein, respectively.

    Full summary, score breakdown and related studies → Original source

  2. 2001-09-17

    Correction of alternative splicing of tau in frontotemporal dementia and parkinsonism linked to chromosome 17

    ✓ Peer-reviewed Drug development The Journal of biological chemistry

    Key finding: Mutations in the human tau gene cause frontotemporal dementia and Parkinsonism associated with chromosome 17 (FTDP-17). +2 more findings

    Full summary, score breakdown and related studies → Original source

  3. 2001-09-01

    Amyloidosis: a convoluted story

    ✓ Peer-reviewed Drug development British Journal of Haematology

    Key finding: However, the fibrils in primary amyloidosis (AL) consist of the variable portion of a monoclonal light chain (κ or λ); secondary amyloidosis (AA) fibrils consist of protein A, a non-immunoglobulin; familial amyloidosis fibrils are usually composed of mutated transthyretin (prealbumin); senile systemic amyloid fibrils consist of normal transthyretin; and amyloid associated with long-term dialysis consists of β2-microglobulin. +4 more findings

    Full summary, score breakdown and related studies → Original source

  4. 2001-09-01

    Normalization of cerebral volumes by use of intracranial volume: implications for longitudinal quantitative MR imaging

    ✓ Peer-reviewed Brain scans and imaging PubMed Central

    Key finding: The TIV normalization of cross-sectional brain volumes significantly reduced interindividual variation; the coefficient of variation (CV) was reduced from 10.0% to 6.0% in controls (P <.001). +4 more findings

    Full summary, score breakdown and related studies → Original source

  5. 2001-09 month only

    Galantamine: a randomized, double-blind, dose comparison in patients with Alzheimer's disease

    ✓ Peer-reviewed Clinical trials International journal of geriatric psychiatry

    Key finding: Patients treated with galantamine 24 mg/day had a significantly better outcome than placebo on ADAS-cog; the treatment difference was 3 points on the intention-to-treat (ITT) analysis ( p = 0.01) and 4.2 points on per protocol analysis ( p = 0.001). +3 more findings

    Full summary, score breakdown and related studies → Original source

  6. 2001-09 month only

    Donepezil in the treatment of patients with Alzheimer's disease

    ✓ Peer-reviewed Treatments Expert review of neurotherapeutics

    Key finding: Clinical placebo-controlled trials and open-label extension studies have consistently shown that donepezil is well tolerated and gives rise to statistically significant improvements in cognition, global function and activities of daily living for at least 12 months and to less deterioration of function possibly for more than 4 years. +1 more finding

    Full summary, score breakdown and related studies → Original source

  7. 2001-09-01

    Neuron number in the entorhinal cortex and CA1 in preclinical Alzheimer disease

    ✓ Peer-reviewed Cognitive tests and assessment Archives of neurology

    Key finding: There is little or no neuronal loss in aging or preclinical AD but substantial loss in very mild AD. +1 more finding

    Full summary, score breakdown and related studies → Original source

  8. 2001-09-01

    Neuropsychiatric aspects of Huntington's disease

    ✓ Peer-reviewed Clinical safety Journal of neurology, neurosurgery, and psychiatry

    Key finding: Neuropsychiatric symptoms are prevalent in Huntington's disease and are relatively independent of cognitive and motor aspects of the disease. +1 more finding

    Full summary, score breakdown and related studies → Original source

  9. 2001-09-01

    Glutamate uptake

    ✓ Peer-reviewed Inflammation and the immune system Progress in neurobiology

    Key finding: The transporter proteins represent the only (significant) mechanism for removal of glutamate from the extracellular fluid and their importance for the long-term maintenance of low and non-toxic concentrations of glutamate is now well documented.

    Full summary, score breakdown and related studies → Original source

  10. 2001-09-01

    Health care management of adults with Down syndrome

    ✓ Peer-reviewed Risk factors American family physician

    Key finding: Patients with Down syndrome are likely to have a variety of illnesses, including thyroid disease, diabetes, depression, obsessive-compulsive disorder, hearing loss, atlantoaxial subluxation and Alzheimer's disease. +4 more findings

    Full summary, score breakdown and related studies → Original source

  11. 2001-09-01

    Cholesterol and Alzheimer's disease: is there a link?

    ✓ Peer-reviewed Drug development Neurology

    Key finding: Two recent epidemiologic studies indicate that there is a decreased prevalence of AD associated with the use of cholesterol-lowering drugs that inhibit 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA reductase inhibitors or statins).

    Full summary, score breakdown and related studies → Original source

  12. 2001-09-01

    The 'Arctic' APP mutation (E693G) causes Alzheimer's disease by enhanced Abeta protofibril formation

    ✓ Peer-reviewed Risk genes beyond APOE Nature neuroscience

    Key finding: Fibrillization studies demonstrated no difference in fibrillization rate, but Abeta with the Arctic mutation formed protofibrils at a much higher rate and in larger quantities than wild-type (wt) Abeta.

    Full summary, score breakdown and related studies → Original source

  13. 2001-09-01

    MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer's disease

    ✓ Peer-reviewed Hippocampus size on brain scans Neurobiology of aging

    Key finding: The two patient groups differed significantly from controls in entorhinal volume, but not from each other; in contrast, they differed from each other, as well as from controls, in hippocampal volume, with the mild AD cases showing the greatest atrophy. +2 more findings

    Full summary, score breakdown and related studies → Original source

  14. 2001-09-01

    MRI-derived entorhinal and hippocampal atrophy in incipient and very mild Alzheimer’s disease

    ✓ Peer-reviewed Brain scans and imaging Neurobiology of Aging

    Full summary, score breakdown and related studies → Original source

  15. 2001-09-01

    Selective preservation and degeneration within the prefrontal cortex in aging and Alzheimer disease

    ✓ Peer-reviewed Brain tissue and pathology Archives of neurology

    Key finding: The prefrontal cortex (PFC) is a heterogeneous cortical structure that supports higher cognitive functions, including working memory and verbal abilities. +3 more findings

    Full summary, score breakdown and related studies → Original source

  16. 2001-09-01

    Homocysteine and cognitive decline in healthy elderly

    ✓ Peer-reviewed Cognitive tests and assessment Dementia and geriatric cognitive disorders

    Key finding: Elevated levels might signal accelerated cognitive decline, although this remains to be established. +3 more findings

    Full summary, score breakdown and related studies → Original source

  17. 2001-09-01

    Applicability of the CERAD neuropsychological battery to Brazilian elderly

    ✓ Peer-reviewed Cognitive tests and assessment Arquivos de neuro-psiquiatria

    Key finding: A Portuguese version of CERAD neuropsychological battery was applied to a control group of healthy elderly (CG) (mean age 75.1 years/ education 7.9 years), 31 Alzheimer disease (AD) patients classified by clinical dementia rating (CDR) as CDR1 (71.4/ 9.0) and 12 AD patients CDR 2 (74.1/ 9.3). +3 more findings

    Full summary, score breakdown and related studies → Original source

  18. 2001-09-01

    Delirium in older medical inpatients and subsequent cognitive and functional status: a prospective study

    ✓ Peer-reviewed Cognitive tests and assessment CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne

    Key finding: Delirium in older hospital inpatients appears to be associated with various adverse outcomes. +3 more findings

    Full summary, score breakdown and related studies → Original source

  19. 2001-09-01

    Reduced levels of amyloid beta-peptide antibody in Alzheimer disease

    ✓ Peer-reviewed Risk genes beyond APOE Neurology

    Key finding: Immunization with preaggregated amyloid beta-peptide (Abeta(1-42)) and administration of antibodies against Abeta into amyloid precursor protein APP(V717F)- transgenic mice (an animal model of AD) have recently been reported to dramatically reduce amyloid plaque deposition, neuritic dystrophy, and astrogliosis, most likely by enhancing Abeta clearance from brain. +3 more findings

    Full summary, score breakdown and related studies → Original source

  20. 2001-09-01

    Alzheimer's disease versus dementia with Lewy bodies: cerebral metabolic distinction with autopsy confirmation

    ✓ Peer-reviewed Lewy body dementia Annals of neurology

    Key finding: Eleven DLB patients (7 Lewy body variant of AD [LBVAD] and 4 pure diffuse Lewy body disease [DLBD]) who had antemortem position emission tomography imaging and autopsy confirmation were compared to 10 autopsy-confirmed pure AD patients. +4 more findings

    Full summary, score breakdown and related studies → Original source

  21. 2001-09-01

    Lewy bodies and parkinsonism in families with parkin mutations

    ✓ Peer-reviewed Lewy body dementia Annals of neurology

    Key finding: Classically, this disease has been associated with loss of dopaminergic neurons in the substantia nigra pars compacta and locus ceruleus, without Lewy body pathology. +3 more findings

    Full summary, score breakdown and related studies → Original source

  22. 2001-09-01

    Spontaneous speech of patients with dementia of the Alzheimer type and mild cognitive impairment

    ✓ Peer-reviewed Digital health tools International psychogeriatrics

    Key finding: This article discusses the potential of three assessments of language function in the diagnosis of Alzheimer-type dementia (DAT). +3 more findings

    Full summary, score breakdown and related studies → Original source

Browse the library by subject, with the full score breakdown →